Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.

Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W, Shapiro DB

Fertility and sterility1 Jan 2001Cited by 160 (Europe PMC)

PMID11163814DOI10.1016/s0015-0282(00)01638-1PepBankPUB-11163814

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women undergoing COH, mean oocytes retrieved per attempt were 11.6 with ganirelix versus 14.1 with leuprolide.
In plain wordsIn women undergoing COH, mean oocytes retrieved were 11.6 with ganirelix versus 14.1 with leuprolide.
Peptide
Ganirelix
Outcome
DecreaseOocytes retrieved per attempt
Study
n = 313
Comparator
Leuprolide acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Mean oocytes retrieved per attempt
11.6 oocytes
ganirelix
Mean oocytes retrieved per attempt
14.1 oocytes
leuprolide
Source sentences
Summary
The mean number of oocytes retrieved per attempt was 11.6 in the ganirelix group and 14.1 in the leuprolide group.
3 context sentences(design, population, supporting numbers)
Summary · context
Phase III, multicenter, open-label randomized trial.
Summary · context
Healthy female partners (n = 313) in subfertile couples for whom COH and IVF or intracytoplasmic sperm injection were indicated.
Summary · context
Patients were randomized to receive one COH cycle with ganirelix or the reference treatment, a long protocol of leuprolide acetate in conjunction with follitropin-beta for injection.
Report a problemFND-1116381401
02HumanRandomized controlled trialEfficacy outcome
In women undergoing COH, fertilization rates were 62.4% with ganirelix versus 61.9% with leuprolide.
In plain wordsIn women undergoing COH, fertilization rates were 62.4% with ganirelix versus 61.9% with leuprolide.
Peptide
Ganirelix
Outcome
Direction not reportedFertilization rate
Study
n = 313
Comparator
Leuprolide acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Fertilization rate
62.4%
ganirelix
Fertilization rate
61.9%
leuprolide
Source sentences
Summary
Fertilization rates were 62.4% and 61.9% in the ganirelix and leuprolide groups, respectively, and implantation rates were 21.1% and 26.1%.
3 context sentences(design, population, supporting numbers)
Summary · context
Phase III, multicenter, open-label randomized trial.
Summary · context
Healthy female partners (n = 313) in subfertile couples for whom COH and IVF or intracytoplasmic sperm injection were indicated.
Summary · context
Patients were randomized to receive one COH cycle with ganirelix or the reference treatment, a long protocol of leuprolide acetate in conjunction with follitropin-beta for injection.
Report a problemFND-1116381402
03HumanRandomized controlled trialEfficacy outcome
In women undergoing COH, implantation rates were 21.1% with ganirelix versus 26.1% with leuprolide.
In plain wordsIn women undergoing COH, implantation rates were 21.1% with ganirelix versus 26.1% with leuprolide.
Peptide
Ganirelix
Outcome
DecreaseImplantation rate
Study
n = 313
Comparator
Leuprolide acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Implantation rate
21.1%
ganirelix
Implantation rate
26.1%
leuprolide
Source sentences
Summary
Fertilization rates were 62.4% and 61.9% in the ganirelix and leuprolide groups, respectively, and implantation rates were 21.1% and 26.1%.
3 context sentences(design, population, supporting numbers)
Summary · context
Phase III, multicenter, open-label randomized trial.
Summary · context
Healthy female partners (n = 313) in subfertile couples for whom COH and IVF or intracytoplasmic sperm injection were indicated.
Summary · context
Patients were randomized to receive one COH cycle with ganirelix or the reference treatment, a long protocol of leuprolide acetate in conjunction with follitropin-beta for injection.
Report a problemFND-1116381403
04HumanRandomized controlled trialEfficacy outcome
In women undergoing COH, clinical pregnancy rates per attempt were 35.4% with ganirelix versus 38.4% with leuprolide.
In plain wordsIn women undergoing COH, clinical pregnancy rates were 35.4% with ganirelix versus 38.4% with leuprolide.
Peptide
Ganirelix
Outcome
Direction not reportedClinical pregnancy rate
Study
n = 313
Comparator
Leuprolide acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Clinical pregnancy rate per attempt
35.4%
ganirelix
Clinical pregnancy rate per attempt
38.4%
leuprolide
Source sentences
Summary
Clinical and ongoing pregnancy rates per attempt were 35.4% and 30.8% in the ganirelix group and 38.4% and 36.4% in the leuprolide acetate group.
3 context sentences(design, population, supporting numbers)
Summary · context
Phase III, multicenter, open-label randomized trial.
Summary · context
Healthy female partners (n = 313) in subfertile couples for whom COH and IVF or intracytoplasmic sperm injection were indicated.
Summary · context
Patients were randomized to receive one COH cycle with ganirelix or the reference treatment, a long protocol of leuprolide acetate in conjunction with follitropin-beta for injection.
Report a problemFND-1116381404
05HumanRandomized controlled trialEfficacy outcome
In women undergoing COH, ongoing pregnancy rates per attempt were 30.8% with ganirelix versus 36.4% with leuprolide.
In plain wordsIn women undergoing COH, ongoing pregnancy rates were 30.8% with ganirelix versus 36.4% with leuprolide.
Peptide
Ganirelix
Outcome
Direction not reportedOngoing pregnancy rate
Study
n = 313
Comparator
Leuprolide acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Ongoing pregnancy rate per attempt
30.8%
ganirelix
Ongoing pregnancy rate per attempt
36.4%
leuprolide
Source sentences
Summary
Clinical and ongoing pregnancy rates per attempt were 35.4% and 30.8% in the ganirelix group and 38.4% and 36.4% in the leuprolide acetate group.
3 context sentences(design, population, supporting numbers)
Summary · context
Phase III, multicenter, open-label randomized trial.
Summary · context
Healthy female partners (n = 313) in subfertile couples for whom COH and IVF or intracytoplasmic sperm injection were indicated.
Summary · context
Patients were randomized to receive one COH cycle with ganirelix or the reference treatment, a long protocol of leuprolide acetate in conjunction with follitropin-beta for injection.
Report a problemFND-1116381405
06HumanRandomized controlled trialSafety outcome
In women undergoing COH, moderate injection site reactions occurred in 11.9% with ganirelix versus 24.4% with leuprolide.
In plain wordsIn women undergoing COH, moderate injection site reactions were less frequent with ganirelix than leuprolide.
Peptide
Ganirelix
Outcome
DecreaseModerate injection site reactions
Study
n = 313
Comparator
Leuprolide acetate
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Moderate injection site reactions
11.9%
ganirelix
Moderate injection site reactions
24.4%
leuprolide
Source sentences
Summary
Fewer moderate and severe injection site reactions were reported with ganirelix (11.9% and 0.6%) than with leuprolide (24.4% and 1.1%).
3 context sentences(design, population, supporting numbers)
Summary · context
Phase III, multicenter, open-label randomized trial.
Summary · context
Healthy female partners (n = 313) in subfertile couples for whom COH and IVF or intracytoplasmic sperm injection were indicated.
Summary · context
Patients were randomized to receive one COH cycle with ganirelix or the reference treatment, a long protocol of leuprolide acetate in conjunction with follitropin-beta for injection.
Report a problemFND-1116381406
07HumanRandomized controlled trialSafety outcome
In women undergoing COH, severe injection site reactions occurred in 0.6% with ganirelix versus 1.1% with leuprolide.
In plain wordsIn women undergoing COH, severe injection site reactions were less frequent with ganirelix than leuprolide.
Peptide
Ganirelix
Outcome
DecreaseSevere injection site reactions
Study
n = 313
Comparator
Leuprolide acetate
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Severe injection site reactions
0.6%
ganirelix
Severe injection site reactions
1.1%
leuprolide
Source sentences
Summary
Fewer moderate and severe injection site reactions were reported with ganirelix (11.9% and 0.6%) than with leuprolide (24.4% and 1.1%).
3 context sentences(design, population, supporting numbers)
Summary · context
Phase III, multicenter, open-label randomized trial.
Summary · context
Healthy female partners (n = 313) in subfertile couples for whom COH and IVF or intracytoplasmic sperm injection were indicated.
Summary · context
Patients were randomized to receive one COH cycle with ganirelix or the reference treatment, a long protocol of leuprolide acetate in conjunction with follitropin-beta for injection.
Report a problemFND-1116381407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT01669291

Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

Main Line Fertility Centern = 43Jul 2012 to May 2014

Fertility

Trial page ClinicalTrials.govUpdated 4 Jun 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.